Trial Results Posted: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (NCT06303167)

WHY IT MATTERS

This trial provides evidence that osimertinib may work against cancers with EGFR mutations across different cancer types, potentially offering a treatment option for patients whose tumors have this specific genetic change.

Researchers tested a cancer drug called osimertinib (AZD9291) in 19 patients with advanced cancers that have specific genetic changes in a gene called EGFR. The drug works by blocking a mutated protein that helps cancer cells grow. This trial is now complete and results have been posted.

NCT ID: NCT06303167 Status: ACTIVE_NOT_RECRUITING Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma Phase: PHASE2 Enrollment: 19 Sponsor: National Cancer Institute (NCI) Summary: This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of mutant forms of the EGFR protein, which play a key role in tumor cell growth. Osimertinib may cause tumor cell death and inhibit tumor growth in EGFR-overexpressing tumor cells, thereby stopping or slowing the spread of

ASK YOUR DOCTOR

If you have advanced cancer with an EGFR mutation, ask your oncologist whether osimertinib or similar EGFR-targeting drugs might be appropriate for your specific cancer type and genetic profile.